Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.
EP. 1: Patient Profile 1: Resection for Early/Intermediate Stage HCC
Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.
EP. 2: Early-Stage HCC: Role of Adjuvant Therapy
A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.
EP. 3: Early-Stage HCC: What is the Role of Neoadjuvant Therapy?
Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.
EP. 4: Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC
Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC
EP. 5: Selection and Use of Systemic Therapy in Intermediate Stage HCC
Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.
EP. 6: Management of HCC: Advances in Biomarkers and Screening
A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.
EP. 7: Patient Profile 2: Frontline Therapy for Advanced HCC
Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.
EP. 8: HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC
Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.
EP. 9: Real-World Selection of Frontline Combination Therapy for Advanced HCC
Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.
EP. 10: Role of Hepatitis Status in Selecting Therapy for HCC
Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.
EP. 11: Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC
Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.
EP. 12: Frontline Therapy for Advanced HCC: Novel Combination Strategies
Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.
EP. 13: Patient Profile 3: Second-Line Therapy for Advanced HCC
Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.
EP. 14: Selecting Therapy for Advanced HCC Following TKI Failure
Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.
EP. 15: Selecting Therapy for Advanced HCC Following Atezo-Bev Failure
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
EP. 16: Later-Line IO Therapy for Advanced Hepatocellular Carcinoma
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.
EP. 17: The Evolving Treatment Landscape of HCC
Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies
Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL
2 Clarke Drive Cranbury, NJ 08512